Intravesical BCG immunotherapy is used after transurethral resection (TUR) for the prevention of recurrence of NMIBC. BCG treatment is usually started a few weeks after TUR and is given once a week for 6 weeks. It stimulates immune responses that can destroy bladder cancer cells (acute and chronic induced inflammations) and as a consequence causes side effects. The investigators postulate that Xpert® test might be used to demonstrate the presence of residual (after TURB) or recurrent (during adjuvant treatment) disease at the time of intravesical treatment, which could be of very significant impact in the management of this complex situation.Urines of BCG treated patients are rich in immune system elements (cytokines, lymphocytes,…), this complex inflammatory milieu of urines may interfere with urinary biomarkers. This study will allow assessing the effect of the complex inflammatory milieu induced by BCG treatment in urines of patients with NMIBC on the Xpert® Bladder cancer assay.

Brief Title

Effect on Xpert® Bladder Test of Urines Inflammatory Milieu Induced by BCG Treatment of Patients With NMIBC

Official Title

Evaluation of the Effect of a Complex Inflammatory Milieu Induced by BCG Treatment in Urines of Patients With Non-muscle-invasive Bladder Cancer on the Xpert® Bladder Cancer Assay

Brief Summary

Intravesical BCG immunotherapy is used after transurethral resection (TUR) for the prevention<br /> of recurrence of NMIBC. BCG treatment is usually started a few weeks after TUR and is given<br /> once a week for 6 weeks. It stimulates immune responses that can destroy bladder cancer cells<br /> (acute and chronic induced inflammations) and as a consequence causes side effects. The<br /> investigators postulate that Xpert® test might be used to demonstrate the presence of<br /> residual (after TURB) or recurrent (during adjuvant treatment) disease at the time of<br /> intravesical treatment, which could be of very significant impact in the management of this<br /> complex situation.Urines of BCG treated patients are rich in immune system elements<br /> (cytokines, lymphocytes,…), this complex inflammatory milieu of urines may interfere with<br /> urinary biomarkers. This study will allow assessing the effect of the complex inflammatory<br /> milieu induced by BCG treatment in urines of patients with NMIBC on the Xpert® Bladder cancer<br /> assay.

Detailed Description

1. Qualification of Xpert® Testing:

Three 50 mL fresh urine samples will be collected in sterile containers according to
Cepheid instructions of use:

- the "baseline sample" before the first BCG instillation,

- the "study sample" taken during the initiation course of treatment instillations,
preferably at the 4th or 5th instillation of BCG therapy,

- the "follow-up sample" at the time of the first follow-up cystoscopy, approximately
3 months after the last BCG instillation of the initiation course.

Xpert® test results will be qualified as positive or negative, according to Cepheid
instructions for use.

Samples tested positive at baseline will not be included in the analysis and the
patient's participation in the study will be discontinued.

Samples obtained in patients with no recurrence at follow-up cystoscopy after the
initiation course will be considered for analysis.

2. Threshold of detection of theXpert® Bladder test:

- One urine sample of a patient tumor free (negative Xpert test) under BCG treatment
will be spiked into 3 log dilutions of the 2 distinct tumor cell lines SW780 and
BE(2)-C (100, 1000, and 10000 cells per ml).

- A mix of fresh and frozen cells from en bloc harvested tumors from distinct donors
will be tested at the set concentration in BCG urines from distinct patients.